Joint (NASDAQ:JYNT) Raised to “Buy” at StockNews.com

StockNews.com upgraded shares of Joint (NASDAQ:JYNT) from a hold rating to a buy rating in a report issued on Monday morning.

Other research analysts also recently issued reports about the stock. Roth Mkm reissued a buy rating and issued a $16.00 price target (up from $13.00) on shares of Joint in a report on Friday, May 3rd. B. Riley boosted their target price on Joint from $12.00 to $20.00 and gave the stock a buy rating in a research report on Monday. Finally, TheStreet cut Joint from a c- rating to a d rating in a report on Thursday, March 7th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Joint has a consensus rating of Moderate Buy and an average price target of $22.00.

Joint Stock Performance

NASDAQ:JYNT opened at $15.93 on Monday. The business’s fifty day moving average is $12.42 and its 200 day moving average is $10.31. The firm has a market cap of $238.54 million, a price-to-earnings ratio of -21.24 and a beta of 1.58. Joint has a 52-week low of $7.31 and a 52-week high of $16.39.

Joint (NASDAQ:JYNT) last announced its quarterly earnings results on Thursday, March 7th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.04. Joint had a positive return on equity of 3.94% and a negative net margin of 9.24%. The firm had revenue of $30.61 million for the quarter, compared to analysts’ expectations of $29.63 million. Equities analysts predict that Joint will post 0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On Joint

A number of hedge funds have recently made changes to their positions in JYNT. Barclays PLC raised its position in Joint by 29.4% in the 3rd quarter. Barclays PLC now owns 13,725 shares of the company’s stock worth $123,000 after purchasing an additional 3,119 shares during the period. Quantbot Technologies LP grew its stake in shares of Joint by 345.0% during the third quarter. Quantbot Technologies LP now owns 4,170 shares of the company’s stock valued at $37,000 after buying an additional 3,233 shares during the last quarter. Bard Associates Inc. increased its holdings in shares of Joint by 4.3% in the fourth quarter. Bard Associates Inc. now owns 79,549 shares of the company’s stock worth $764,000 after buying an additional 3,250 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Joint by 43.3% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 16,506 shares of the company’s stock valued at $148,000 after acquiring an additional 4,987 shares during the last quarter. Finally, Trexquant Investment LP boosted its holdings in Joint by 8.0% during the 4th quarter. Trexquant Investment LP now owns 82,686 shares of the company’s stock valued at $795,000 after acquiring an additional 6,097 shares during the period. 76.88% of the stock is currently owned by institutional investors.

Joint Company Profile

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.